Novartis’ and BMS’ paused CAR T trials, RevMed’s pancreatic cancer approval, more MFN deals

Novartis and Bristol-Myers Squibb have paused several CAR T trials for autoimmune conditions following patient deaths and safety concerns, highlighting potential risks associated with rapid manufacturing processes. Meanwhile, the White House has expanded its Most Favored Nation drug pricing initiative to include nine mid-sized biotechs, now covering approximately 89% of the branded drug market. In clinical developments, the FDA granted an early approval to Revolution Medicines for its pancreatic cancer therapy, while BioNTech discontinued a colorectal cancer vaccine trial due to futility. Additionally, Eli Lilly continues its aggressive acquisition strategy with a $3 billion deal for Merida Biosciences, and Roche is deepening its footprint in Asia through multi-billion dollar partnerships focused on T-cell engagers and antibody-drug conjugates. These developments underscore a volatile landscape for oncology and immunology, marked by both rapid regulatory breakthroughs and significant clinical setbacks.